Plitt Sabrina S, Kichuk Ryan, Geier Sheena, Smith Trenton, Roy Felicia, Severini Alberto, Charlton Carmen L
Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
J Assoc Med Microbiol Infect Dis Can. 2021 Jul 20;6(2):94-103. doi: 10.3138/jammi-2020-0048. eCollection 2021 Jun.
Persistent infection with a subset of human papillomavirus (HPV) genotypes can cause abnormal cytology and invasive cervical cancer. This study examines the circulating HPV genotype strains in a local population of the province of Alberta (a largely unvaccinated population) to establish baseline frequency of vaccine and non-vaccine genotypes causing abnormal cervical cytology.
Remnant liquid-based cytology specimens from the Alberta Cervical Cancer Screening Program (March 2014-January 2016) were examined. Only specimens from women who had a cytology grading of atypical squamous cells of undetermined significance or higher were included. HPV genotype was determined for all samples, and results were stratified by demographics and cytology results.
Forty-four unique HPV genotypes were identified from 4,794 samples. Of the 4,241 samples with a genotype identified, the most common genotypes were HPV 16, 18, 31, and 51, with 1,599 (37.7%), 441 (12.2%), 329 (7.8%), and 354 (8.4%), respectively. HPV9 vaccine genotypes made up 73.2% of these genotyped samples. Compared with specimens in which HPV9 vaccine genotypes were not detected, those with a genotype covered by the HPV9 vaccine were from younger women (33 [interquartile range {IQR] 28 to 42] y versus 40 [IQR 32 to 51] y; < 0.00001).
The baseline distribution of HPV genotypes in this largely unvaccinated population indicates that the HPV9 vaccine provides good protection from high-risk HPV infections. Determining the frequency of genotypes causing abnormal cytology in this population post-vaccine implementation will be important to assess efficacy of vaccination and monitor for any potential genotype replacement.
感染一部分人乳头瘤病毒(HPV)基因型会导致细胞学异常及浸润性宫颈癌。本研究检测了艾伯塔省当地人群(大部分未接种疫苗)中循环的HPV基因型毒株,以确定导致宫颈细胞学异常的疫苗和非疫苗基因型的基线频率。
检测了艾伯塔省宫颈癌筛查项目(2014年3月至2016年1月)留存的液基细胞学标本。仅纳入细胞学分级为意义不明确的非典型鳞状细胞或更高分级的女性标本。对所有样本进行HPV基因型测定,并按人口统计学和细胞学结果进行分层。
从4794份样本中鉴定出44种独特的HPV基因型。在4241份鉴定出基因型的样本中,最常见的基因型为HPV 16、18、31和51,分别有1599份(37.7%)、441份(12.2%)、329份(7.8%)和354份(8.4%)。HPV9疫苗基因型占这些基因分型样本的73.2%。与未检测到HPV9疫苗基因型的标本相比,检测到HPV九价疫苗覆盖基因型的标本来自更年轻的女性(33岁[四分位间距{IQR}28至42岁]对40岁[IQR 32至51岁];P<0.00001)。
在这个大部分未接种疫苗的人群中,HPV基因型的基线分布表明HPV9疫苗对高危HPV感染提供了良好的保护。在疫苗接种后确定该人群中导致细胞学异常基因型的频率,对于评估疫苗接种效果和监测任何潜在的基因型替代至关重要。